DRL says taking corrective actions after FDA warning letter

DRL shares on Monday stumbled by 3.44 percent over previous close to Rs 3,504.60 on BSE.

Unichem gets USFDA nod for hypertension treatment tablets

Unichem gets USFDA nod for hypertension treatment tablets

Pharmaceutical firm Unichem Laboratories has received US FDA approval for the Losartan Potassium tablets used in treatment of hypertension.

Haldiram's food products to be tested for pesticides in Maharashtra

After the US FDA reportedly found pesticides in Haldiram's products, Maharashtra has too ordered a test.

Trans fats banned in US: How bad are they? Should India follow suit?

The US Food and Drug Administration's directive to remove artificial trans fats from processed foods can act as an eye-opener for millions of Indians, considering the adverse affects that it has on the human health.

Potential drug candidates for Ebola found

Scientists, including one of Indian-origin, have found new potential drug candidates for Ebola that successfully treated up to 90 percent of mice exposed to the deadly virus.

US FDA approves sale of Strides Arcolab's HIV treatment drug

Bangalore-based Strides Arcolab Friday said US health regulator has approved its drug used for treating HIV infection in adult and children for sale in US market.

IPCA Labs aims to make plants US FDA-compliant by December

IPCA Laboratories Ltd is aiming to make all of its plants facing import alerts from the United States compliant with U.S. Food and Drug Administration (FDA) rules by December, an executive said on Wednesday.

IPCA slumps as FDA bans imports from 2 more plants

Shares in generic drugmaker IPCA Laboratories slumped as much 12.7 percent, heading towards their biggest daily fall since July 2014, after the U.S. Food and Drug Administration (FDA) issued an import alert against two of its plants.

US FDA did not find issues with Wockhardt's Chikalthana plant

"The recent inspection at the Aurangabad L1-Chikalthana site was a follow-up inspection by the US FDA as an outcome of completion of good manufacturing practise (GMP) remediation submitted by Wockhardt in October 2014.

US FDA approves 23andMe genetic screening test for rare disorder

Google-backed 23andMe won U.S. approval on Thursday to market the first direct-to-consumer genetic test for a mutation that can cause children to inherit Bloom syndrome, a rare disorder that leads to short height, an increased risk of cancer and unusual facial features.

US FDA knew devices spread fatal ''superbug'' but does not order fix

US health regulators have known since at least 2009 that the medical devices at the center of the "superbug" outbreak at UCLA can transmit lethal infections but have not recommended any new safety requirements, a lapse that threatens patient safety, experts in hospital-acquired infections said.

Wockhardt drug discovery gets fast track approval by USFDA

Wockhardt today said its new drug discovery programme in anti-infective research has received a major boost after two of its drugs, WCK 771 and WCK 2349, received the Qualified Infectious Disease Product (QIDP)status from the US FDA.

FDA raises concern over drug production process at Cadila

The FDA inspected the Moraiya plant, based in Gujarat, in the second week of July.

FDA bans imports from Canadian drugmaker Apotex's India plant

The U.S. Food and Drug Administration banned imports from Canadian drugmaker Apotex Inc`s manufacturing plant in India for not complying with quality standards, the latest in a series of sanctions against medicines produced in India.

Sun Pharma gets FDA import ban on Gujarat plant

The plant in Karkhadi in Gujarat makes both drug ingredients and formulations, according to Sun`s 2013 annual report.

US bans bidis made by Indian tobacco company

US regulators Friday banned the sale and import of small cigarettes known as bidis made by an Indian company, their first such action since being given oversight of tobacco products in 2009.

Sensex falls over 200 points, Ranbaxy slumps nearly 20%

Sensex slipped by over 200 points in the late morning trade to fall further from its record closing high pulled down by shares of Ranbaxy which fell about 20 percent following the banned of products by US FDA.

Ranbaxy falls around 16% after FDA bans products

Shares in Ranbaxy Laboratories Ltd, majority owned by Japan`s Daiichi Sankyo Co Ltd, slumped around 16 percent in early trade after the US Food and Drug Administration banned more products from the Indian drugmaker.

Ranbaxy Laboratories hit again as US FDA bans more products

In a setback to Indian pharmaceutical giant Ranbaxy, the US has prohibited the company from producing and distributing drugs for the American market from its Toansa facility in Punjab.

Drugmakers urge FDA security audit after cyber breach

The US Food and Drug Administration is under pressure from the pharmaceutical industry and lawmakers to undergo an independent security audit, after hackers broke into a computer system used by healthcare companies to submit information to the agency.